Skip to Content
Morningstar

Aadi Bioscience Inc AADI

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.78 −0.06 (3.26%)
View Full Chart
As of Delayed Price Post-Trading: $1.78 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
AADI is trading at a 56% discount.
Price
$1.90
Fair Value
$8.85
Uncertainty
Extreme
1-Star Price
$34.35
5-Star Price
$8.98
Economic Moat
Ytn
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AADI is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$1.84
Day Range
$1.76–1.85
52-Week Range
$1.55–8.60
Bid/Ask
$1.78 / $1.79
Market Cap
$43.71 Mil
Volume/Avg
110,341 / 363,633

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.03
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
89
Website
https://www.aadibio.com

Comparables

Valuation

View More
Metric
AADI
PRLD
CRBU
Price/Earnings (Normalized)
 ———
Price/Book Value
 0.430.860.96
Price/Sales
 2.03—8.52
Price/Cash Flow
 ———
Price/Earnings
AADI
PRLD
CRBU

Financial Strength

Metric
AADI
PRLD
CRBU
Quick Ratio
 6.1010.6711.75
Current Ratio
 6.4810.7911.97
Interest Coverage
 −301.71——
Quick Ratio
AADI
PRLD
CRBU

Profitability

Metric
AADI
PRLD
CRBU
Return on Assets (Normalized)
 −34.57%−38.93%−23.27%
Return on Equity (Normalized)
 −40.82%−43.41%−28.24%
Return on Invested Capital (Normalized)
 −45.00%−42.59%−26.03%
Return on Assets
AADI
PRLD
CRBU
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHbzgmkxlrJvzqz$557.8 Bil
VRTX
Vertex Pharmaceuticals IncMmnvhmvkMfrnzt$104.7 Bil
REGN
Regeneron Pharmaceuticals IncJyrlggdzBzgzz$99.6 Bil
MRNA
Moderna IncBgddjzwKzhxm$38.8 Bil
ARGX
argenx SE ADRYlttcsmxbZrjvc$21.4 Bil
BNTX
BioNTech SE ADRMknndkmGwqr$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncCfqvyqrkTycdk$18.4 Bil
BMRN
Biomarin Pharmaceutical IncKjnsfplmJjkhsw$17.5 Bil
RPRX
Royalty Pharma PLC Class ANwsytzfxtQjxxrf$12.4 Bil
INCY
Incyte CorpCgzvmklpYyhnkb$11.9 Bil

Sponsor Center